Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xeljanz Development Plans Scaled Back By Pfizer

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm will deprioritize development of the oral JAK inhibitor in Crohn’s disease, ankylosing spondylitis and potentially psoriasis, while focusing on expansion in psoriatic arthritis and ulcerative colitis.

You may also be interested in...

Pfizer Xeljanz: Duration Of 10 mg Dose In Ulcerative Colitis Could Hinge On Post-Market Commitment

Postmarket trial looking at reduced doses in UC may be difficult to enroll, Pfizer argues; with approval of expanded indication seeming assured, another postmarket question for Xeljanz could look at impact of herpes zoster vaccine.

Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes

US FDA's Gastrointestinal Drugs Advisory Committee says higher dosing regimens can be used despite agency worries about safety with long-term use.

Pfizer Xeljanz's Long-term Dosing Raises Safety Concerns In Ulcerative Colitis

US FDA's Gastrointestinal Drugs Advisory Committee will weigh proposed indication as agency appears uncertain whether higher dose can be used as long-term therapy.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts